Cargando…

Biosimilars 101: considerations for U.S. oncologists in clinical practice

Biosimilars of biologics used for cancer treatment and supportive care are expected to enter the U.S. market soon. Biosimilars will be highly similar to their reference products, but unlike generic drugs, not identical. Differences between a biosimilar and its reference product may arise because of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camacho, Luis H, Frost, Craig P, Abella, Esteban, Morrow, Phuong K, Whittaker, Sadie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303156/ https://www.ncbi.nlm.nih.gov/pubmed/24810680 http://dx.doi.org/10.1002/cam4.258

Ejemplares similares

Assessing patients’ risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
por: Lyman, Gary H, et al.
Publicado: (2015)

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists
por: Mileham, Kathryn F., et al.
Publicado: (2021)

Practical Considerations for Integrating Biosimilars Into Clinical Practice
por: May, Megan B., et al.
Publicado: (2021)

What do oncologists need to know about biosimilar products?
por: Leung, Linda K. S., et al.
Publicado: (2016)

Considerations for the US health-system pharmacist in a world of biosimilars
por: Zlatkus, Andrea, et al.
Publicado: (2020)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns
por: Resende, Heloísa M., et al.
Publicado: (2021)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015)

Clinical considerations for biosimilar antibodies
por: Mellstedt, Håkan
Publicado: (2013)

Being present: oncologists' role in promoting advanced cancer patients' illness understanding
por: Cohen, Simon M., et al.
Publicado: (2018)

Associations between cancer and Alzheimer's disease in a U.S. Medicare population
por: Freedman, Daryl Michal, et al.
Publicado: (2016)

Current status and considerations on biosimilar in China
por: Wang, Junzhi
Publicado: (2012)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Oncologists' attitudes toward KRAS testing: a multisite study
por: Harris, Julie N, et al.
Publicado: (2013)

Opioid prescription patterns among radiation oncologists in the United States
por: Huang, Tina Q., et al.
Publicado: (2020)

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
por: Salgia, Nicholas J., et al.
Publicado: (2021)

Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients
por: Papautsky, Elizabeth Lerner, et al.
Publicado: (2022)

Sugar- and Artificially-Sweetened Beverages and Cancer Mortality in a Large U.S. Prospective Cohort
por: McCullough, Marjorie, et al.
Publicado: (2022)

Managing an Older Adult with Cancer: Considerations for Radiation Oncologists
por: Chang, Sanders, et al.
Publicado: (2017)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Practical considerations for postarrest targeted temperature management
por: Mullen, Isabelle, et al.
Publicado: (2020)

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
por: Illouz, Frédéric, et al.
Publicado: (2017)

A U.S. population‐based study of insurance disparities in cancer survival among adolescents and young adults
por: Colton, Meryl D., et al.
Publicado: (2019)

Fatherhood status in relation to prostate cancer risks in two large U.S.‐based prospective cohort studies
por: Geczik, Ashley M., et al.
Publicado: (2020)

Cross-Cultural Considerations in U.S. Research Ethics Education
por: Heitman, Elizabeth
Publicado: (2014)

Street Medicine: Barrier Considerations for Healthcare Providers in the U.S.
por: Tito, Emmanuel
Publicado: (2023)

Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
por: Kolberg, Hans-Christian, et al.
Publicado: (2021)

Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support
por: Lee, Alfred Ian, et al.
Publicado: (2022)

Oncologists' perceived barriers to an expanded role for primary care in breast cancer survivorship care
por: Neuman, Heather B., et al.
Publicado: (2016)

Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists
por: McNamara, Donna M., et al.
Publicado: (2019)

Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know
por: Gorzo, Alecsandra, et al.
Publicado: (2022)

Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations
por: Teller, Craig F., et al.
Publicado: (2021)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Biosimilars: Key regulatory considerations and similarity assessment tools
por: Kirchhoff, Carol F., et al.
Publicado: (2017)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_urhos4c16iri30ruif0tu99dsa